Temporary Reauthorization of the Emergency Scheduling of Fentanyl Analogues Act

Temporary Reauthorization of the Emergency Scheduling of Fentanyl Analogues Act

This bill extends until May 6, 2022, the temporary scheduling order issued by the Drug Enforcement Administration to place fentanyl-related substances in schedule I of the Controlled Substances Act. The temporary order expires on May 6, 2021.

Bill 117 HR 2430, also known as the Temporary Reauthorization of the Emergency Scheduling of Fentanyl Analogues Act, is a piece of legislation that aims to extend the temporary scheduling of fentanyl analogues by the Drug Enforcement Administration (DEA). Fentanyl analogues are synthetic opioids that are chemically similar to fentanyl and have been linked to a rise in overdose deaths in the United States.

The bill was introduced in response to the expiration of the temporary scheduling of fentanyl analogues, which was set to expire on February 6, 2020. The temporary scheduling allows the DEA to classify fentanyl analogues as Schedule I controlled substances, making it illegal to manufacture, distribute, or possess these substances without proper authorization.

The Temporary Reauthorization of the Emergency Scheduling of Fentanyl Analogues Act seeks to extend this temporary scheduling for an additional 15 months, giving Congress more time to consider a more permanent solution to the issue of fentanyl analogues. The bill also includes provisions for the DEA to conduct a study on the impact of fentanyl analogues on public health and safety, as well as recommendations for how to address the issue moving forward. Overall, the Temporary Reauthorization of the Emergency Scheduling of Fentanyl Analogues Act is a bipartisan effort to combat the opioid crisis by extending the temporary scheduling of fentanyl analogues and providing additional resources for research and prevention efforts.